Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022

GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) --  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials. Details for the oral presentation are as follows: Title: The Emerging Weight Loss Therapeutics and Implications for the NASH Treatment Paradigm Presenter: Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. Date/Time: Friday, May 27, 2022 at 3:15 pm BST A copy of Dr. Harris’ presentation will be accessible on the Events section of the Altimmune website. Details for the panel discussion are as follows: Title: Clinical Endpoints for NASH Trials Moderator: Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. Date/Time: Friday, May 27, 2022 at 9:35 am BST About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter Investor & Media Contacts: Richard Eisenstadt                                                         Chief Financial Officer                                                  Phone: 240-654-1450                                                         [email protected] Source: Altimmune, Inc

The release as fetched from its publisher. altimmune.com ↗